530 results on '"Raffoux E"'
Search Results
2. POS0954 CLINICAL FEATURES AND GENOMIC LANDSCAPE OF MYELOPROLIFERATIVE NEOPLASM (MPN) PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASES
3. GERMLINE CHEK2 MUTATED MDS PATIENTS
4. Prognostic value of PET / CT and CT in T‐cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients
5. Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
6. Prise en charge du patient neutropénique en réanimation (nouveau-nés exclus). Recommandations d’un panel d’experts de la Société de réanimation de langue française (SRLF) avec le Groupe francophone de réanimation et urgences pédiatriques (GFRUP), la Société française d’anesthésie et de réanimation (Sfar), la Société française d’hématologie (SFH), la Société française d’hygiène hospitalière (SF2H) et la Société de pathologies infectieuses de langue française (SPILF)
7. Long-term survival following post-allograft relapse of T-cell acute lymphoblastic leukaemia: a novel approach using nelarabine and donor lymphocyte infusions
8. Prise en charge du patient neutropénique en réanimation (nouveau-nés exclus). Recommandations d’un panel d’experts de la Société de réanimation de langue française (SRLF) avec le Groupe francophone de réanimation et urgences pédiatriques (GFRUP), la Société française d’anesthésie et de réanimation (Sfar), la Société française d’hématologie (SFH), la Société française d’hygiène hospitalière (SF2H) et la Société de pathologies infectieuses de langue française (SPILF)
9. O08 - GERMLINE CHEK2 MUTATED MDS PATIENTS
10. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study
11. P374: BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY
12. PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY
13. Prognostic value of PET/CT and CT in T‐cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.
14. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
15. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia
16. Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML
17. A retrospective series of gut aspergillosis in haematology patients
18. Caractéristiques phénotypiques et mutationnelles des maladies auto-immunes et inflammatoires (MAI) associées aux néoplasies myéloprolifératives (NMP)
19. O24 - Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: APR 246 PLUS AZACITIDINE (AZA) IN TP53 MUTATED (M) MDS AND AML. LONG TERM FOLLOW UP OF PHASE 2 STUDY BY THE GFM
20. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
21. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III
22. Granulomatoses cutanées clonales au cours des hémopathies myéloïdes : série de 11 cas
23. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)
24. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS
25. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
26. Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)
27. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML
28. PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL
29. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
30. Traitement des leucémies aiguës promyélocytaires de l’adulte
31. In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy
32. Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations
33. Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group
34. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
35. Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study
36. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
37. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
38. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia
39. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group
40. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate
41. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials
42. Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein–Barr virus infection. A different subtype of AILD-TL?
43. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy
44. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007
45. Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study
46. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
47. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia
48. Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome
49. Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia
50. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.